CTMX
NASDAQ · Biotechnology
Cytomx Therapeutics Inc
$2.81
+0.05 (+1.81%)
Open$2.79
Previous Close$2.76
Day High$2.81
Day Low$2.74
52W High$8.21
52W Low$1.93
Volume—
Avg Volume3.79M
Market Cap602.49M
P/E Ratio—
EPS$-0.44
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+2,143.4% upside
Current
$2.81
$2.81
Target
$63.04
$63.04
$39.26
$63.04 avg
$88.15
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 118.02M | 104.70M | 145.29M |
| Net Income | -26,898,468 | -21,476,775 | 18.60M |
| Profit Margin | -22.8% | -21.7% | 12.8% |
| EBITDA | -32,731,098 | -27,585,648 | 25.56M |
| Free Cash Flow | — | — | 18.27M |
| Rev Growth | +12.7% | +12.7% | +5.8% |
| Debt/Equity | — | — | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |